Brief: Brainstorm Granted Patents For Allogeneic Exosome Platform-Product In Neurological Disorder Treatments
26/12/2023 13:10
Dec 26 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM GRANTED PATENTS FOR ALLOGENEIC EXOSOME
PLATFORM-PRODUCT IN NEUROLOGICAL DISORDER TREATMENTS
Source text for Eikon: ID:nPn97ncGKa
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview